Research and Markets: Investment Opportunities in Chinese Pharmaceutical Industry as China joins the World Trade Organization (WTO)

Research and Markets has announced the addition of Business Opportunities in China: The impact of the WTO to their offering.

(PRWEB) October 13, 2004 -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Business Opportunities in China: The impact of the WTO to their offering.

China has established a pharmaceutical industry structure, and has become one of the largest pharmaceutical-producing countries in the world. The Chinese pharmaceutical industry has increased in value with an annual average growth rate of16.72% over the last few decades. However, the industry is still small-scale, with a scattered geographical layout, duplicated production processes, and outdated manufacturing technology and management structure. The Chinese pharmaceutical industry also has a lower market concentration and weak international trading competitiveness, coupled with a lack of patented pharmaceuticals developed in-house. As China joins the World Trade Organization (WTO), it will need to integrate more completely into the global economy.

This international competition will place an intense pressure on the Chinese pharmaceutical industry, and further open the door to a lucrative market for non-Chinese companies, especially for pharmaceutical producers and manufacturers. Accession to the WTO will bind China by fundamental WTO principles, such as improved transparency and the strengthening of commercial legal procedures. China's WTO commitments include the tightening of rules on intellectual property, tariff concessions, and market access of non-Chinese service suppliers engaging in the distribution of pharmaceuticals. All such moves will create additional business opportunities for non-Chinese pharmaceutical companies in China, and in turn, place an intense pressure on the Chinese pharmaceutical industry.

This report will discuss the state of the Chinese pharmaceutical industry and the opportunities available to companies doing business in China, based on Chinese official statistics. Section 2 provides an overview of the development of the Chinese pharmaceutical industry, and its current status. Section 3 discusses the competitiveness of the Chinese pharmaceutical industry in the international market. Section 4 provides an analysis of the business opportunities for pharmaceutical firms considering alliances in China, based on this research and the commitments made by Chinese authorities at the time of accession to the WTO. The report concludes (section 5) by highlighting the significant points for consideration for companies looking to capture such business opportunities in China. The appendices (section 6) include two case studies that explore examples of a 'Sino-foreign equity joint venture' and a 'Wholly foreign-owned company' in China, references, a glossary of terms, the source data used in the figures, and a resources section.

Information provided includes:
- An overview of the pharmaceutical industry in China
- Competing in the international market
- Business opportunities for non-Chinese pharmaceutical firms in China

For more information visit http://www.researchandmarkets.com/reports/c7118

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###